<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781233</url>
  </required_header>
  <id_info>
    <org_study_id>H15-29504</org_study_id>
    <nct_id>NCT02781233</nct_id>
  </id_info>
  <brief_title>A Progressive Resistance Training Program in Patients With Haemophilia</brief_title>
  <official_title>The Impact of Progressive Resistance Training on Quality of Life in Patients With Haemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical impact of a progressive resistance training program in
      adults patients with haemophilia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The training program aims improving muscular strength and endurance in the relevant muscles
      and joints (knee, elbow, ankle, shoulder and hip) in order to improve the quality of life in
      the patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Muscle strength</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>For measuring the isometric knee flexion and extension, ankle plantarflexion and dorsiflexion strength and isometric elbow flexion and extension strength, a portable hand-held dynamometer will be used (Nicholas Manual Muscle Tester, Lafayette Instruments, Indiana, USA).
A hand dynamometer with adjustable grip (TKK 5101 Grip D, Takei, Tokyo Japan) will be used for measuring handgrip strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in stair test</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haemophilia Quality of life questionnaire (A36 Haemophilia-QoL® )</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body composition</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Muscle ultrasound (Logic C5 Premium (GE Medical Systems, China, CO., LTD) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood analysis</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle activation</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>A surface EMG system will be used to evaluate the neuromuscular effect of the training program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleedings</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Bleeding assessment tool and thermal images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Postural balance</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>For the static postural balance measurement, a NEDSVE/IBV force platform will be used (Biomechanics Institute of Valencia, Valencia, Spain). Two tests with different levels of difficulty will be performed: Romberg test with Eyes Open and Romberg test with Eyes Closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in timed up and go</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sit-to-stand test</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 30 meters walk test</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haemophilia Activities List questionnaire</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The Haemophilia Joint Health Score (HJHS)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analogue Scale (pain)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in synovitis state</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Muscle ultrasound (Logic C5 Premium (GE Medical Systems, China, CO., LTD) will be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Haemophilia</condition>
  <arm_group>
    <arm_group_label>Training group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will participate in 2 sessions each week during 12 weeks, with 3 days of difference (rest) between the sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual daily activities</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Progressive resistance training</intervention_name>
    <arm_group_label>Training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal daily activities</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of haemophilia A or B

          -  willingness to exercise twice a week during the training program and to complete the
             pre- and post-program evaluations

          -  approval by their hematologist to participate in the exercise program

          -  age between 18 and 60 years

          -  informed consent signed.

        Exclusion Criteria:

          -  the inability to attend exercise sessions at least twice a week for 6 consecutive
             weeks

          -  non adherence to instruction on proper exercise technique

          -  surgical procedures performed 6 weeks prior to or during the exercise program

          -  participation in any other form of exercise, including rehabilitation, during the
             study; (5) changes in medication during the study

          -  a major bleeding episode that posed a risk or prevented exercise

          -  History of FVIII inhibitor (titer ≥ 0.6 BU [Bethesda unit]) or detectable FVIII
             inhibitors at screening (titer ≥ 0.4 BU)

          -  Another haemostatic defect

          -  Need for major surgery

          -  Withdrawal of informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Querol-Fuentes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofía Pérez-Alenda, PT, PhD</last_name>
    <phone>+34963983853</phone>
    <phone_ext>64022</phone_ext>
    <email>Sofia.Perez-Alenda@uv.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sofía Pérez-Alenda, PT, PhD</last_name>
      <email>Sofia.Perez-Alenda@uv.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Valencia</investigator_affiliation>
    <investigator_full_name>Felipe Querol Fuentes</investigator_full_name>
    <investigator_title>Medical doctor, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

